Understanding the Digital Signals That Influence AI Recommendations

Claims in this piece are observable and methodological — no client or benchmark data used.

A pharmaceutical buyer asks an AI assistant: “Which CDMOs in India can manufacture sterile injectable products for regulated markets?” The assistant returns several companies. The interesting part is not simply which names appear — it is how each company is described.

One may be described as a general pharmaceutical manufacturer. Another may be associated with sterile fill-finish. A third may be described around oral solid dosage. The companies themselves have not suddenly changed. What has changed is the information the system has been able to connect to the buyer’s question.

That is the useful way to think about digital signals and AI Visibility. A company’s actual capabilities are one thing. Its public record is another. What an AI assistant can establish from that public record is a third. The parent article, When AI Recommends a CDMO, What Is It Actually Evaluating?, explores that distinction in full. This supporting piece focuses on one narrower question: what signals in the public record make a genuine CDMO capability easier — or harder — for an AI assistant to establish?

The signals are not “AI signals”

There is a temptation to think of AI Visibility as a technical problem requiring some special form of optimisation. That is usually the wrong starting point. The more practical question is whether the digital record contains clear, specific, consistent and supportable information about the business.

Consider a CDMO with genuine sterile fill-finish capability. Its website might say: “We provide integrated pharmaceutical solutions across a broad range of dosage forms.” That may be true. But it gives an outside researcher very little to connect with the buyer asking about sterile injectable manufacturing.

Elsewhere, perhaps a facility page identifies sterile fill-finish. An old company presentation mentions lyophilised injectables. A regulatory document contains relevant information. The commercial website, however, never brings those facts together. Inside the organisation, everyone knows the capability exists. Outside it, the signal is fragmented — and an AI assistant does not have access to the internal conversation. It has to work with what it can establish.

What digital signals should a CDMO inspect?

The parent article uses four practical questions for inspecting an AI representation: relevance, specificity, support and accuracy. Those same four are useful when looking at the digital record that sits underneath the representation.

• Relevance. Does the public information connect the organisation to the actual buyer requirement? If the buyer is looking for sterile injectable manufacturing, does the public record clearly establish sterile injectables? If they need an HPAPI-capable partner, is high-potency handling clearly associated with the relevant manufacturing operation? A list of services is not necessarily the same thing as relevance — the buyer’s question has to meet the company’s evidence.
• Specificity. Specificity gives an outside researcher something concrete to establish. “Comprehensive pharmaceutical solutions” is broad; “sterile fill-finish for lyophilised injectable products” is specific. “Serving regulated markets” is broad; naming the relevant regulatory markets is more informative where the claim can be supported. A useful test: could a technically competent person tell exactly what this company does from the statement alone? If not, it may be too broad to carry commercial meaning.
• Support. A capability statement becomes more useful when there is supporting information behind it — a relevant facility description, regulatory information, technical documentation, or another credible source. This is where manufacturers need discipline: a website should not make claims merely because they sound commercially attractive. The objective is not more claims. It is a more supportable record.
• Accuracy. Does the digital record still reflect the business? This is where long-lived pharmaceutical websites become problematic. A facility may have changed. A dosage form may no longer be a priority. A capability may have expanded. An old PDF can keep circulating long after the commercial website has moved on. An AI assistant may then construct a representation from information that is individually plausible but collectively inconsistent — which usually means the public record itself needs attention.

What should you look for on your own website?

For each important capability, a practical review checks five things — a self-contained legibility test:

• What you make — is the specific dosage form or capability stated, not just implied by a service list?
• Where you make it — is the facility, and its manufacturing role, clearly identified?
• For which markets — is the relevant regulatory/market context named where it can be supported?
• In what specific context — is the genuine specialisation (HPAPI, lyophilisation, technology transfer) distinguished from generic “end-to-end” language?
• Currency and coherence — is the information current, and consistent across every public source?

That is the useful signal — not whether the page contains enough marketing language, not whether the company calls itself “leading,” not whether the website looks modern. The test is whether the relevant business fact survives contact with a real buyer question. This matters most for specialist CDMOs: a manufacturer may have excellent depth in a narrow area, but if the public record describes it only as a broad “end-to-end” provider, the specialist capability is hard for an outside researcher to establish. That is a legibility problem, not a capability problem.

How can you test whether the signals are working?

Do not begin by asking an AI assistant “tell me about our company” — that tests company summarisation, not the situation a buyer creates. Instead, reproduce the kind of question a buyer might actually ask:

Which CDMOs in India can manufacture sterile injectable products for regulated markets?

Run that same prompt through ChatGPT, Gemini, Perplexity, Claude and Copilot. Record the complete responses, with platform and date. Then inspect your own representation by asking each assistant: “Why did you include [Company Name]?”, then “What public evidence supports that assessment?”, then “What important capability information about [Company Name] is unclear or missing?”

The useful findings are not simply whether your company appears. Look at whether the representation is accurate or inaccurate, specific or generic, complete or missing an important capability, supported or unsupported, consistent or contradictory. That is a reproducible observation, not a benchmark — responses change with platform, prompt, available information and time, so it should not be treated as proof of how AI “works” universally. It is a way of observing what an AI-assisted buyer can currently establish about your business.

Why consistency matters more than adding more content

One of the easiest mistakes is to respond to an AI Visibility problem by publishing more material. More pages do not automatically create a clearer public record — in fact they can make it worse if different pages describe the same business differently. Imagine the homepage says “injectables,” the facility page says “sterile fill-finish,” an older PDF says “lyophilised injectables,” the LinkedIn profile emphasises oral solids, and none explains which capability applies to which site. There may be plenty of information, but no clean story. That is why coherence is itself a digital signal: the goal isn’t every page repeating the same sentence, it’s the important facts fitting together. The wider website implications are covered in Your Pharmaceutical Website Is No Longer Just a Brochure and Seven Trust Signals Every Pharmaceutical Website Should Demonstrate.

What this means for CDMO leadership

AI Visibility should not be treated as an exercise in making an AI assistant say something more favourable — that misses the point. The better objective is to make the real business easier to understand accurately. If your company genuinely has sterile fill-finish capability, make it clear. If you genuinely serve regulated international markets, make the relevant evidence discoverable. If a facility has a particular manufacturing role, explain it. If an old public statement is no longer accurate, correct it. And if important information cannot appropriately be made public, recognise that an outside system may not be able to establish it — no amount of optimisation changes that constraint. The commercial question is straightforward: does the public record give an AI-assisted buyer enough accurate information to understand why this CDMO is relevant to the question they are asking?

Where Emerivo fits

Emerivo is a specialist advisory serving pharmaceutical manufacturing and research organisations — TPMs, CMOs, CDMOs and CROs. Its focus is AI Visibility: understanding how AI assistants find, interpret and represent these organisations when buyers research potential partners. Emerivo delivers this through the AI Discovery Audit™, which does not promise rankings or recommendations — no credible organisation can guarantee those. Instead it tests realistic buyer questions across ChatGPT, Gemini, Perplexity, Claude and Copilot and records what each platform can establish, what it gets wrong, and what it cannot establish clearly. The starting point is not “how do we make AI recommend us?” but “what can an AI-assisted buyer accurately establish about us today?”

For the full argument, start with the parent cornerstone: When AI Recommends a CDMO, What Is It Actually Evaluating?

Frequently asked questions